Aspirin Use to Prevent Cardiovascular Disease

医学 阿司匹林 心肌梗塞 冲程(发动机) 疾病 风险评估 内科学 重症监护医学 计算机安全 计算机科学 机械工程 工程类
作者
Karina W. Davidson,Michael J. Barry,Carol M. Mangione,Michael D. Cabana,David Chelmow,Tumaini R. Coker,Esa M. Davis,Katrina E Donahue,Carlos Roberto Jaén,Alex H. Krist,Martha Kubik,Li Li,Gbenga Ogedegbe,Lori Pbert,John Ruiz,James Stevermer,Chien‐Wen Tseng,John B. Wong
出处
期刊:JAMA [American Medical Association]
卷期号:327 (16): 1577-1577 被引量:230
标识
DOI:10.1001/jama.2022.4983
摘要

Importance

Cardiovascular disease (CVD) is the leading cause of mortality in the US, accounting for more than 1 in 4 deaths. Each year, an estimated 605 000 people in the US have a first myocardial infarction and an estimated 610 000 experience a first stroke.

Objective

To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD. The systematic review also investigated the effect of aspirin use on colorectal cancer (CRC) incidence and mortality in primary CVD prevention populations, as well as the harms (particularly bleeding) associated with aspirin use. The USPSTF also commissioned a microsimulation modeling study to assess the net balance of benefits and harms from aspirin use for primary prevention of CVD and CRC, stratified by age, sex, and CVD risk level.

Population

Adults 40 years or older without signs or symptoms of CVD or known CVD (including history of myocardial infarction or stroke) who are not at increased risk for bleeding (eg, no history of gastrointestinal ulcers, recent bleeding, other medical conditions, or use of medications that increase bleeding risk).

Evidence Assessment

The USPSTF concludes with moderate certainty that aspirin use for the primary prevention of CVD events in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk has a small net benefit. The USPSTF concludes with moderate certainty that initiating aspirin use for the primary prevention of CVD events in adults 60 years or older has no net benefit.

Recommendation

The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit. (C recommendation) The USPSTF recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults 60 years or older. (D recommendation)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
虾滑完成签到,获得积分10
刚刚
深情夏彤完成签到,获得积分10
刚刚
刚刚
111发布了新的文献求助10
1秒前
h1352216完成签到 ,获得积分10
2秒前
2秒前
phz完成签到,获得积分10
2秒前
princeadam完成签到,获得积分10
2秒前
爆米花应助小郝采纳,获得10
2秒前
3秒前
4秒前
帅气小蜜蜂完成签到,获得积分20
4秒前
5秒前
Artorias发布了新的文献求助10
6秒前
xx发布了新的文献求助20
7秒前
难过冷玉发布了新的文献求助10
7秒前
蓝开心发布了新的文献求助10
8秒前
自信号厂应助尼古拉斯采纳,获得10
9秒前
共享精神应助尼古拉斯采纳,获得10
9秒前
NMC发布了新的文献求助30
11秒前
无敌大忽悠完成签到,获得积分10
11秒前
隐形曼青应助瓜酱酱采纳,获得10
11秒前
李爱国应助焕颜采纳,获得10
12秒前
12秒前
乐乐应助枫枫829采纳,获得10
13秒前
14秒前
天天快乐应助动听的梦容采纳,获得30
14秒前
CMCM发布了新的文献求助10
14秒前
李健应助54不得了采纳,获得10
14秒前
15秒前
小郝发布了新的文献求助10
16秒前
萧水白应助聪明的从梦采纳,获得10
17秒前
hdh发布了新的文献求助10
18秒前
guyanlong发布了新的文献求助10
20秒前
123发布了新的文献求助10
20秒前
21秒前
吓我一跳完成签到,获得积分10
22秒前
22秒前
22秒前
小巧曼安完成签到 ,获得积分10
23秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Gerard de Lairesse : an artist between stage and studio 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3072205
求助须知:如何正确求助?哪些是违规求助? 2726027
关于积分的说明 7492250
捐赠科研通 2373536
什么是DOI,文献DOI怎么找? 1258633
科研通“疑难数据库(出版商)”最低求助积分说明 610333
版权声明 596952